title: [LDL-cholesterol control in patients with genetic dyslipidemia followed up by Lipid and Vascular Risk Units of the Spanish Society of Arteriosclerosis].
abstract: OBJECTIVE
  To evaluate low-density lipoprotein-cholesterol (LDLc) achieved in patients with genetic dyslipidemia treated during one year in Lipid and Vascular Risk Units (LVRU) of the Spanish Society of Arteriosclerosis (SSA).
  
  
  METHODS
  Observational, longitudinal, retrospective, multicenter national study that included consecutive patients of both sexes over 18 years of age referred due to dyslipidemia to LVRU of the SSA. Information was collected from medical records corresponding to two visits in the lipid unit.
  
  
  RESULTS
  A total of 527 patients (mean age 48 years, 60.0% men) diagnosed with genetic dyslipidemia (241 with heterozygous familial hypercholesterolemia, and 286 with familial combined hyperlipidemia) were included. The mean follow-up was 12.9 months. In the last visit, 94% were taking statins, one third combined with ezetimibe, although only 41% were taking a high-intensity hypolipidemic treatment. Overall, 28.5% of patients attained an LDLc level<100 mg/dL, 35.8% decreased their LDLc by >50%, and 53.8% achieved one of the two. Predictors of target LDLc levels in the multivariate analysis were age, smoking habit and the presence of vascular disease.
  
  
  CONCLUSIONS
  Over half of the patients with genetic dyslipidemia followed up by LVRU of SSA achieve LDLc objectives after one year of follow-up. The use of high-intensity hypolipidemic treatment could improve these results.
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Hospital Carlos III, Madrid, España. Electronic address: clahoz.hciii@salud.madrid.org.
authors.forename: Carlos
authors.initials: C
authors.lastname: Lahoz
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Hospital Carlos III, Madrid, España.
authors.forename: José María
authors.initials: JM
authors.lastname: Mostaza
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Hospital Universitario de Bellvitge, Universitat de Barcelona, CIBERobn-ISCIII, Barcelona, España.
authors.forename: Xavier
authors.initials: X
authors.lastname: Pintó
authors.affiliation: Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid, Madrid, España.
authors.forename: Juan José
authors.initials: JJ
authors.lastname: de la Cruz
authors.affiliation: Departamento de Medicina Preventiva y Salud Pública, Universidad Autónoma de Madrid, Madrid, España.
authors.forename: José Ramón
authors.initials: JR
authors.lastname: Banegas
authors.affiliation: Unidad de Lípidos, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España.
authors.forename: Juan
authors.initials: J
authors.lastname: Pedro-Botet
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood*; D004359:Drug Therapy, Combination; D000069438:Ezetimibe / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006950:Hyperlipidemia, Familial Combined / Q000188:drug therapy*; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D013030:Spain; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069438:Ezetimibe
keywords: Estatinas; Ezetimiba; Ezetimibe; Familial combined hyperlipidemia; Familial hypercholesterolemia; Hipercolesterolemia familiar; Hiperlipidemia familiar combinada; Statins